We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
Read MoreHide Full Article
Key Takeaways
UTHR won a ruling that Liquidia infringes two patent claims covering inhaled treprostinil use in PH-ILD.
Yutrepia may lose its PH-ILD label or face market removal, subject to the final judgment and FDA action.
UTHR could benefit from reduced competition and plans to seek monetary damages for past infringement.
United Therapeutics (UTHR - Free Report) announced that it has received a favorable ruling in its patent litigation against Liquidia Technologies (LQDA - Free Report) concerning the latter’s lead product, Yutrepia, a dry-powder inhaled formulation of treprostinil. UTHR shares rose nearly 13% following the announcement.
United Therapeutics and Liquidia Technologies compete directly in the market for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH) market through their inhaled treprostinil products, with UTHR offering Tyvaso and Tyvaso DPI and LQDA competing with its newly launched dry-powder formulation, Yutrepia.
United Therapeutics has been marketing Tyvaso for PAH since 2009 and expanded its label to PH-ILD in 2021. The company subsequently received FDA approval for Tyvaso DPI in 2022 for PAH and PH-ILD. Meanwhile, the FDA approved Yutrepia in May 2025 for the treatment of PAH and PH-ILD and began commercialization in June 2025.
The U.S. District Court for the District of Delaware ruled that Liquidia infringes claims one and 14 of United Therapeutics’ ’327 patent. The patent covers the use of inhaled treprostinil at specific doses to improve exercise capacity in patients with PH-ILD.
The court rejected Liquidia’s arguments that these two claims were invalid. This ruling strengthens United Therapeutics’ position in protecting its PH-ILD franchise.
Year to date, shares of United Therapeutics have risen 11.2% against the industry’s 4.4% decline.
Image Source: Zacks Investment Research
Potential Impact on LQDA’s Yutrepia
The ruling could create significant challenges for Liquidia’s Yutrepia. United Therapeutics believes the court could order the FDA to withdraw Yutrepia’s approval under the relevant patent law provisions. If the court issues such an order, Yutrepia could be removed from the U.S. market until Liquidia obtains FDA approval for a label that excludes the PH-ILD indication.
However, the outcome is not yet certain. The court has given both companies one week to submit an agreed form of final judgment. If they cannot agree on the appropriate remedies, the court will decide the matter.
UTHR Could Benefit From Reduced Competition
A restriction on Yutrepia's PH-ILD use could benefit United Therapeutics, as the company already markets two inhaled treprostinil products for this indication, nebulized Tyvaso and the Tyvaso DPI formulation. These Tyvaso products are the key drivers of the company’s top line. The company could therefore see less competitive pressure in the PH-ILD market if Yutrepia loses its PH-ILD indication or faces broader market restrictions.
United Therapeutics has stated that it is prepared to help patients transition to Tyvaso products if PH-ILD is removed from the Yutrepia label. This could help the company retain patients who currently use Yutrepia.
The patent dispute could also have a financial benefit beyond future competition. United Therapeutics intends to seek monetary damages for past infringement.
The potential damages could include a royalty on past Yutrepia sales. However, the ultimate commercial and financial impact will depend on the final judgment, any FDA action and the outcome of Liquidia’s potential appeals.
UTHR's Zacks Rank & Stocks to Consider
United Therapeutics currently carries a Zacks Rank #3 (Hold).
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 24 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 73 cents. PGEN shares have gained 104.8% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents per share. ACIU shares have lost 16.6% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
View the Zacks #1 Rank List
Image: Bigstock
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
Key Takeaways
United Therapeutics (UTHR - Free Report) announced that it has received a favorable ruling in its patent litigation against Liquidia Technologies (LQDA - Free Report) concerning the latter’s lead product, Yutrepia, a dry-powder inhaled formulation of treprostinil. UTHR shares rose nearly 13% following the announcement.
United Therapeutics and Liquidia Technologies compete directly in the market for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH) market through their inhaled treprostinil products, with UTHR offering Tyvaso and Tyvaso DPI and LQDA competing with its newly launched dry-powder formulation, Yutrepia.
United Therapeutics has been marketing Tyvaso for PAH since 2009 and expanded its label to PH-ILD in 2021. The company subsequently received FDA approval for Tyvaso DPI in 2022 for PAH and PH-ILD. Meanwhile, the FDA approved Yutrepia in May 2025 for the treatment of PAH and PH-ILD and began commercialization in June 2025.
The U.S. District Court for the District of Delaware ruled that Liquidia infringes claims one and 14 of United Therapeutics’ ’327 patent. The patent covers the use of inhaled treprostinil at specific doses to improve exercise capacity in patients with PH-ILD.
The court rejected Liquidia’s arguments that these two claims were invalid. This ruling strengthens United Therapeutics’ position in protecting its PH-ILD franchise.
Year to date, shares of United Therapeutics have risen 11.2% against the industry’s 4.4% decline.
Image Source: Zacks Investment Research
Potential Impact on LQDA’s Yutrepia
The ruling could create significant challenges for Liquidia’s Yutrepia. United Therapeutics believes the court could order the FDA to withdraw Yutrepia’s approval under the relevant patent law provisions. If the court issues such an order, Yutrepia could be removed from the U.S. market until Liquidia obtains FDA approval for a label that excludes the PH-ILD indication.
However, the outcome is not yet certain. The court has given both companies one week to submit an agreed form of final judgment. If they cannot agree on the appropriate remedies, the court will decide the matter.
UTHR Could Benefit From Reduced Competition
A restriction on Yutrepia's PH-ILD use could benefit United Therapeutics, as the company already markets two inhaled treprostinil products for this indication, nebulized Tyvaso and the Tyvaso DPI formulation. These Tyvaso products are the key drivers of the company’s top line. The company could therefore see less competitive pressure in the PH-ILD market if Yutrepia loses its PH-ILD indication or faces broader market restrictions.
United Therapeutics has stated that it is prepared to help patients transition to Tyvaso products if PH-ILD is removed from the Yutrepia label. This could help the company retain patients who currently use Yutrepia.
The patent dispute could also have a financial benefit beyond future competition. United Therapeutics intends to seek monetary damages for past infringement.
The potential damages could include a royalty on past Yutrepia sales. However, the ultimate commercial and financial impact will depend on the final judgment, any FDA action and the outcome of Liquidia’s potential appeals.
UTHR's Zacks Rank & Stocks to Consider
United Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) and AC Immune (ACIU - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 24 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 73 cents. PGEN shares have gained 104.8% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents per share. ACIU shares have lost 16.6% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.